Apraclonidine
- Atc Codes:S01EA03
- CAS Codes:73218-79-8#66711-21-5
- PHARMGKB ID:73218-79-8#66711-21-5
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
Brand Names
Europe
Austria: Iopidine; Belgium: Iopidine; Bulgaria: Iopidine; Denmark: Iopidine; Finland: Iopidine; France: Iopidine; Germany: Iopidine; Greece: Iopidine; Ireland: Iopidine; Italy: Iopidine; Luxembourg: Iopidine; Netherlands: Iopidine; Poland: Iopidine; Portugal: Iopidine; Spain: Iopimax; Sweden: Iopidine; UK: Iopidine.
North America
Canada: Iopidine; USA: Apraclonidine, Iopidine.
Latin America
Mexico: Iopidine.
Asia
Japan: Iopidine.
Drug combinations
Chemistry
Apraclonidine Hydrochloride: C~9~H~10~Cl~2~N~4~ HCl. Mw: 281.57. (1) 1,4-Benzenediamine, 2,6-dichloro-N^1^-2-imidazolidinylidene-, monohydrochloride; (2) 2-[(4-Amino-2,6-dichlorophenyl)imino]imidazolidine monohydrochloride. CAS-73218-79-8; CAS-66711-21-5 (apraclonidine)(1988).
Pharmacologic Category
Eye, Ear, Nose, and Throat Drugs, Miscellaneous; Ophthalmic α~2~- Agonist. (ATC-Code: S01EA03).
Mechanism of action
Reduction of aqueous humor formation.
Therapeutic use
Prevention and treatment of postsurgical intraocular pressure elevation. Short-term, adjunctive therapy in additional reduction of intraocular pressure.
Pregnancy and lactiation implications
Embryocidal effects were observed in some animal studies. There are as yet no adequate and well-controlled studies in pregnant women. Use with caution during lactation.
Unlabeled use
Contraindications
Hypersensitivity to apraclonidine, clonidine, or any component of the formulation. Use with or within 14 days of MAO inhibitors.
Warnings and precautions
Use with caution in cardiovascular disease, coronary insufficiency, or recent myocardial infarction. Use with caution in history of vasovagal reactions. The intraocular pressure-lowering efficacy observed during the first month of therapy may not always reflect the long-term level of intraocular pressure reduction.